# Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

> **NCT03497806** · PHASE2 · COMPLETED · sponsor: **Finch Research and Development LLC.** · enrollment: 132 (actual)

## Conditions studied

- Clostridium Difficile Infection
- Recurrent Clostridium Difficile Infection
- C. Diff
- CDI
- Recurrent C. Diff
- rCDI
- C. Difficile
- Recurrent CDI
- FMT
- Fecal Microbiota
- Fecal Transplant

## Interventions

- **BIOLOGICAL:** CP101

## Key facts

- **NCT ID:** NCT03497806
- **Lead sponsor:** Finch Research and Development LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-04-01
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2022-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03497806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03497806, "Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03497806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*